So should Cullinan Therapeutics ( NASDAQ:CGEM) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash ...

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) had its price objective boosted by investment analysts at HC Wainwright from $28.00 to $33.00 in a research note issued to investors on Wednesday, ...

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report)’s share price gapped up before the market opened on Wednesday after HC Wainwright raised their price target on the stock from $28.00 to $33.

Cullinan Therapeutics and its partner Taiho Pharmaceutical have reported a win for zipalertinib, with the primary endpoint of a Phase IIb trial being met. The data, which include a positive safety ...

Halcones Precious Metals Corp. (TSXV: HPM) (the "Company” or "Halcones”) is pleased to announce that it has completed the transactio ...

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on ...

In a report released today, Julian Harrison from BTIG maintained a Buy rating on Cullinan Management (CGEM – Research Report), with a price ...

Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. have announced the successful outcome ...

Taiho Pharmaceutical and Taiho Oncology reported that a Phase 1/2 study of the drug zipalertinib met its primary endpoint of overall response rate in a study of EGFR lung cancer patients. The drug was ...

H.C. Wainwright raised the firm’s price target on Cullinan Therapeutics (CGEM) to $33 from $28 and keeps a Buy rating on the shares after the ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...